Skip to main content

Costs and Cost-Effectiveness of New Technologies in Cancer

  • Chapter
Cancer Policy: Research and Methods

Part of the book series: Cancer Treatment and Research ((CTAR,volume 97))

Abstract

The delivery of healthcare has changed significantly, from the perspective of both physicians and patients, in recent years. Previously, the physician was the advocate of the patient, and the insurer was only a distant, third-party observer who picked up the bill at the end. There were many advantages to this system of care: the patient received high quality care and could be relatively sure that his physician was doing everything possible for him, physicians were free to operate in a relatively independent manner which was professionally satisfying, and America was home to some of the most cutting-edge technologies in the world.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Secretary of Health and Human Services, Health United States 1995. Washington D.C.: Government Printing Office, 1996.

    Google Scholar 

  2. Smith TJ, Hillner B, Neighbors DM, McSorley PA, LeChevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cysplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13(9):2166–73.

    PubMed  CAS  Google Scholar 

  3. Bennett CL, Waters TM, Pajeau TS, Pavletic ZS, Tarantolo SR, Bishop MR. Valuing clinical strategies early in development: A cost analysis of allogeneic peripheral blood stem cell transplantation. Ann Int Med, 1998, under review.

    Google Scholar 

  4. McKay NL, Phillips KM. An economic evaluation of mandatory premarital testing for HIV. Inquiry 1991; 28:236–248.

    PubMed  CAS  Google Scholar 

  5. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. J Am Med Assoc 1996; 276(14): 1172–77.

    Article  CAS  Google Scholar 

  6. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommendations on cost-effectiveness in health and medicine. J Am Med Assoc 1996; 276(15):1253–58.

    Article  CAS  Google Scholar 

  7. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. J Am Med Assoc 1996; 276(16): 1339–41.

    Article  CAS  Google Scholar 

  8. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.

    Google Scholar 

  9. National Center for Health Statistics. “Reporting of hospitalization in the health interview survey.” In Vital and Health Statistics, Series 2, No. 6, Washington DC: U.S. Government Printing Office, 1965.

    Google Scholar 

  10. National Center for Health Statistics. “Health interview responses compared with medical records.” In Vital and Health Statistics, Series 2, No. 7, Washington DC: U.S. Government Printing Office, 1966.

    Google Scholar 

  11. National Center for Health Statistics. “Net differences in interview data on chronic conditions and information derived from medical records.” In Vital and Health Statistics, Series 2, No. 57, Washington DC: U.S. Government Printing Office, 1973.

    Google Scholar 

  12. Harlow SD, Linet MS. Agreement between questionnaire data and medical records: the evidence for accuracy of recall. Am J Epidemiol 1989; 129:233

    PubMed  CAS  Google Scholar 

  13. Bryant HE, Visser N, Love EJ. Records, recall, loss, and recall bias in pregnancy: a comparison of interview and medical records data of pregnant and postnatal women. Am J Pub Health 1989; 79:78

    Article  PubMed  CAS  Google Scholar 

  14. Brown JB, Adams ME. Patients as reliable reporters of medical care process: a recall of ambulatory encounter events. Medical Care 1992; 30(5): 400–411.

    Article  PubMed  CAS  Google Scholar 

  15. Bennett CL, Golub R, Waters TM, Tallman M, Rowe JM. Economic analyses of phase III cooperative cancer group clinical trials: Are they feasible? Cancer Invest 1997; 15(3): 227–235.

    PubMed  CAS  Google Scholar 

  16. Lave JR, Pashos CL, Anderson GF, Brailer D, Bubolz T, Conrad D, Freund DA, Fox SH, Keeler E, Lipscomb J, Luft HS, Provenzano G. Costing medical care: Using Medicare administrative data. Medical Care 1994; 32(7): JS77–JS89.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Kluwer Academic Publishers

About this chapter

Cite this chapter

Waters, T.M. (1998). Costs and Cost-Effectiveness of New Technologies in Cancer. In: Bennett, C.L., Stinson, T.J. (eds) Cancer Policy: Research and Methods. Cancer Treatment and Research, vol 97. Springer, Boston, MA. https://doi.org/10.1007/978-0-585-30498-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-0-585-30498-4_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-7923-8203-4

  • Online ISBN: 978-0-585-30498-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics